<i>In vitro</i> elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumabSara Caratelli, Giuseppe Sconocchia, Roberto Arriga et al.|International Journal of Cancer|2019Cited by 43
CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximabRoberto Arriga, Giuseppe Sconocchia, Giulia Lanzilli et al.|International Journal of Cancer|2019Cited by 28
Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomesHany E. Marei, Giuseppe Sconocchia, Asma Al-Thani et al.|Biochemical Pharmacology|2019Cited by 25
Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatmentGiuseppe Sconocchia, Giulio C. Spagnoli, Giulia Lanzilli et al.|Life Science Alliance|2022Cited by 6
CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to CetuximabRoberto Arriga, Giuseppe Sconocchia, Sara Caratelli et al.|bioRxiv (Cold Spring Harbor Laboratory)|2019Cited by 4